Ballicules.com

Trimipramine

SURMONTIL

What it isTertiary amine tricyclic; depression with prominent insomnia.

Why this oneIt preserves sleep architecture more than other tricyclics, which suits depression with severe insomnia.

What limits itHeavily sedating and anticholinergic; lethal in overdose. Weight gain.

FDA-approved for

FDA label

BOXED WARNING Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; not approved for pediatric use.
FDA dosingPopulationStartTargetMax
DepressionOutpatient adults75 mg/day (divided)150 mg/day200 mg/day
DepressionHospitalized adults100 mg/day (divided)200 mg/day250–300 mg/day
DepressionAdolescent/geriatric50 mg/day100 mg/day100 mg/day

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Category C; animal embryotoxicity/anomalies at ~20× human dose; use only if benefit justifies risk

Lactation Undefined

⚠ BOXED WARNING

Cost, est. cash$10–$500/month

Generic entry1987

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger4 / 4
Weight-gain liability2 / 4
Sedation liability3 / 4
QT / Torsades2 / 4
Direct muscarinic antagonism3 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityTricyclic anticholinergic and cardiac toxicity become life-threatening in overdose.

Mechanism of action: Trimipramine ballicule

Trimipramine ballicule: receptor binding, kinetics and half-life diagram

Open Trimipramine in the interactive console ↗

Memory aids: mascots and interaction avatars

Trimipramine SURMONTIL mascot mnemonic cartoon
“Sermon ‘til trimming”
Trimipramine CYP2C19 substrate avatar
CYP2C19 substrate
Trimipramine CYP2D6 substrate avatar
CYP2D6 substrate

Open Trimipramine in the interactive console ↗